IL113433A - Tablet formulations comprising amoxycillin and salts of clavulanic acid - Google Patents

Tablet formulations comprising amoxycillin and salts of clavulanic acid

Info

Publication number
IL113433A
IL113433A IL11343395A IL11343395A IL113433A IL 113433 A IL113433 A IL 113433A IL 11343395 A IL11343395 A IL 11343395A IL 11343395 A IL11343395 A IL 11343395A IL 113433 A IL113433 A IL 113433A
Authority
IL
Israel
Prior art keywords
amoxycillin
salts
clavulanic acid
tablet formulations
formulations
Prior art date
Application number
IL11343395A
Other languages
English (en)
Other versions
IL113433A0 (en
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10754044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL113433(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of IL113433A0 publication Critical patent/IL113433A0/xx
Publication of IL113433A publication Critical patent/IL113433A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
IL11343395A 1994-04-23 1995-04-20 Tablet formulations comprising amoxycillin and salts of clavulanic acid IL113433A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9408117A GB9408117D0 (en) 1994-04-23 1994-04-23 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
IL113433A0 IL113433A0 (en) 1995-07-31
IL113433A true IL113433A (en) 2003-06-24

Family

ID=10754044

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11343395A IL113433A (en) 1994-04-23 1995-04-20 Tablet formulations comprising amoxycillin and salts of clavulanic acid

Country Status (35)

Country Link
US (1) US6051255A (zh)
EP (5) EP0978276B1 (zh)
JP (1) JP3622975B2 (zh)
CN (1) CN1134258C (zh)
AP (2) AP564A (zh)
AT (6) ATE226074T1 (zh)
AU (1) AU684949B2 (zh)
BG (1) BG62842B1 (zh)
BR (1) BR9507502A (zh)
CA (1) CA2188496A1 (zh)
CZ (2) CZ11376U1 (zh)
DE (5) DE69528204T2 (zh)
DK (4) DK0978276T3 (zh)
DZ (1) DZ1876A1 (zh)
ES (4) ES2182754T3 (zh)
FI (1) FI964249A0 (zh)
GB (1) GB9408117D0 (zh)
GR (2) GR3035031T3 (zh)
HK (5) HK1036404A1 (zh)
HU (1) HU228399B1 (zh)
IL (1) IL113433A (zh)
MA (1) MA23528A1 (zh)
MY (1) MY115351A (zh)
NO (1) NO310703B1 (zh)
NZ (1) NZ285080A (zh)
OA (1) OA10377A (zh)
PL (1) PL316966A1 (zh)
PT (4) PT761218E (zh)
RO (1) RO116997B1 (zh)
RU (1) RU2152213C1 (zh)
SA (1) SA95160343B1 (zh)
SI (1) SI0758235T1 (zh)
SK (1) SK282594B6 (zh)
WO (1) WO1995028927A1 (zh)
ZA (1) ZA953236B (zh)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DZ2028A1 (fr) * 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
HUP9901437A3 (en) * 1995-09-07 2000-03-28 Smithkline Beecham Plc Pharmaceutical formulation, containing amoxycillin and clavulanate
AT407701B (de) * 1996-08-12 2001-05-25 Biochemie Gmbh Zur direkttablettierung geeignete mischung, die als wesentliche komponenten amoxicillin-trihydrat und das kaliumsalz der clavulansäure enthält und verfahren zur herstellung dieser mischung
TWI225402B (en) 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GB9616536D0 (en) * 1996-08-06 1996-09-25 Quadrant Holdings Cambridge Co-amoxiclav dosage form
GB9617780D0 (en) * 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
WO1998034598A2 (en) * 1997-02-07 1998-08-13 Gist-Brocades B.V. Homogeneous granulated formulations for dose sipping technology
KR100499812B1 (ko) * 1997-02-14 2005-07-08 스미스클라인 비참 코포레이션 아목시실린 및 클라불라네이트를 포함하는 약제학적 제형
US20030124187A1 (en) * 1997-02-14 2003-07-03 Smithkline Beecham Laboratoires Pharmaceutiques, Pharmaceutical formulations comprising amoxycillin and clavulanate
WO1999011261A1 (en) * 1997-08-29 1999-03-11 Dsm N.V. Granules free of excipients
US6326028B1 (en) 1997-10-31 2001-12-04 Monsanto Company Alginate and gellan gum as tablet coating
WO2000041478A2 (en) 1999-04-01 2000-07-20 Dsm N.V. Agglomerates by crystallisation
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
US6294199B1 (en) * 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
BE1013309A5 (fr) * 1999-04-13 2001-11-06 Beecham Pharm Pte Ltd Formulations pharmaceutiques nouvelles comprenant l'amoxycilline et du clavulanate de potassium.
US20040038948A1 (en) * 1999-12-07 2004-02-26 Uhrich Kathryn E. Therapeutic compositions and methods
GB9930578D0 (en) * 1999-12-23 2000-02-16 Smithkline Beecham Plc Pharmaceutical formulations
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
WO2002002081A1 (en) * 2000-07-05 2002-01-10 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and methods of using same
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
EP1330236A2 (en) * 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
AU2003210925A1 (en) * 2002-02-07 2003-09-02 Rutgers, The State University Antibiotic polymers
GB0203528D0 (en) * 2002-02-14 2002-04-03 Glaxo Group Ltd Process and composition
WO2003068193A1 (en) * 2002-02-14 2003-08-21 Glaxo Group Limited Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
CA2406592C (en) * 2002-10-04 2003-09-30 Duchesnay Inc. Method of preparing pharmaceutical dosage forms containing multiple active ingredients
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
EP1648407A4 (en) 2003-07-21 2011-08-31 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, CORRESPONDING USE AND FORMULATION
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
WO2005009364A2 (en) * 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
US8758820B2 (en) * 2003-08-11 2014-06-24 Shionogi Inc. Robust pellet
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
DE10341264A1 (de) * 2003-09-04 2005-03-24 Grünenthal GmbH Schmelzformulierte, multipartikuläre orale Darreichungsform
JP2007513869A (ja) * 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
JP2007527904A (ja) 2004-03-08 2007-10-04 プロシディオン・リミテッド グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
KR100638315B1 (ko) * 2004-07-23 2006-10-25 주식회사 대웅제약 다중 필름 코팅된 코어층을 갖는 클라불라네이트 및아목시실린-함유 유핵정
TWI367755B (en) 2005-05-20 2012-07-11 Sankyo Co Film coated product
KR100780553B1 (ko) * 2005-08-18 2007-11-29 한올제약주식회사 메트포르민 서방정 및 그의 제조방법
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CL2008003230A1 (es) * 2007-11-01 2009-11-27 Sanofi Aventis Healthcare Pty Ltd Composicion de recubrimiento de tableta que comprende polimero celulosico, plastificante, edulcorante y composicion de sabor en polvo la que comprende saborizante asociado con portador solido; fluido de recubrimiento de tableta que comprende dicha composicion; tableta farmaceutica; proceso de preparacion de dicha tableta.
SI2477611T1 (sl) * 2009-09-18 2017-07-31 Sanofi Formulacije tablete (Z)-2-ciano-3-hidroksi-but-2-enojska kislina-(4'-trifluormetilfenil)-amida z izboljšano stabilnostjo
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
JP6041591B2 (ja) * 2011-09-13 2016-12-14 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
GB1508977A (en) 1974-04-20 1978-04-26 Beecham Group Ltd Beta-lactam antibiotic from streptomyces clavuligerus
US4098897A (en) * 1975-04-14 1978-07-04 Beecham Group Limited Anti bacterial agents
JO984B1 (en) 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
DE3266580D1 (en) * 1981-12-02 1985-10-31 Beecham Group Plc Pharmaceutical formulation comprising beta-lactam antibiotics
GB9408117D0 (en) * 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
BE1013309A5 (fr) * 1999-04-13 2001-11-06 Beecham Pharm Pte Ltd Formulations pharmaceutiques nouvelles comprenant l'amoxycilline et du clavulanate de potassium.
EP1330236A2 (en) * 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin

Also Published As

Publication number Publication date
AU684949B2 (en) 1998-01-08
HK1036404A1 (en) 2002-01-04
BG62842B1 (bg) 2000-09-29
HUT76335A (en) 1997-08-28
DE69528608D1 (de) 2002-11-21
DZ1876A1 (fr) 2002-02-17
DK0761218T3 (da) 2000-12-18
EP0761218A1 (en) 1997-03-12
PT761218E (pt) 2001-03-30
PL316966A1 (en) 1997-03-03
FI964249A (fi) 1996-10-22
AT5349U1 (de) 2002-06-25
CA2188496A1 (en) 1995-11-02
SK282594B6 (sk) 2002-10-08
AP9500733A0 (en) 1995-04-30
EP0758235A1 (en) 1997-02-19
CZ294168B6 (cs) 2004-10-13
EP0758235B1 (en) 2001-07-18
AT5350U1 (de) 2002-06-25
GR3036844T3 (en) 2002-01-31
AP564A (en) 1996-11-21
DK0758235T3 (da) 2001-10-29
PT1093813E (pt) 2003-02-28
HK1009936A1 (en) 1999-06-11
PT758235E (pt) 2001-10-31
MA23528A1 (fr) 1995-12-31
BG100933A (en) 1997-07-31
SA95160343B1 (ar) 2005-05-04
EP1093813B1 (en) 2002-10-16
DK0978276T3 (da) 2003-01-20
NO964488L (no) 1996-12-17
DE29522153U1 (de) 2000-04-06
DE69519093T2 (de) 2001-07-19
GR3035031T3 (en) 2001-03-30
DE69528204T2 (de) 2003-08-07
HK1021860A1 (en) 2000-07-07
DE69521799D1 (de) 2001-08-23
CN1149829A (zh) 1997-05-14
GB9408117D0 (en) 1994-06-15
ES2152485T3 (es) 2001-02-01
FI964249A0 (fi) 1996-10-22
NO310703B1 (no) 2001-08-20
HU9602922D0 (en) 1996-12-30
DK1093813T3 (da) 2003-02-17
DE69528204D1 (de) 2002-10-17
ES2161288T3 (es) 2001-12-01
EP1093813A2 (en) 2001-04-25
RO116997B1 (ro) 2001-09-28
EP1093813A3 (en) 2001-05-30
EP1243267A3 (en) 2002-10-30
ZA953236B (en) 1995-12-27
IL113433A0 (en) 1995-07-31
EP0978276A3 (en) 2000-04-12
BR9507502A (pt) 1997-09-02
CZ11376U1 (cs) 2001-07-12
NO964488D0 (no) 1996-10-22
ES2182754T3 (es) 2003-03-16
AP9600868A0 (en) 1996-10-31
EP0978276A2 (en) 2000-02-09
ATE223706T1 (de) 2002-09-15
WO1995028927A1 (en) 1995-11-02
US6051255A (en) 2000-04-18
MY115351A (en) 2003-05-31
SK135496A3 (en) 1997-05-07
OA10377A (en) 2001-11-21
HK1027024A1 (en) 2001-01-05
HK1050992A1 (zh) 2003-07-18
ATE203161T1 (de) 2001-08-15
ATE196845T1 (de) 2000-10-15
CN1134258C (zh) 2004-01-14
DE69521799T2 (de) 2002-06-13
JPH09512027A (ja) 1997-12-02
ATE226074T1 (de) 2002-11-15
AU2406895A (en) 1995-11-16
PT978276E (pt) 2003-01-31
NZ285080A (en) 1998-05-27
DE69519093D1 (de) 2000-11-16
JP3622975B2 (ja) 2005-02-23
ES2180251T3 (es) 2003-02-01
SI0758235T1 (en) 2001-10-31
EP1243267A2 (en) 2002-09-25
DE69528608T2 (de) 2003-06-26
RU2152213C1 (ru) 2000-07-10
HU228399B1 (en) 2013-03-28
EP0978276B1 (en) 2002-09-11
EP0761218B1 (en) 2000-10-11
CZ309096A3 (en) 1997-04-16

Similar Documents

Publication Publication Date Title
IL113433A0 (en) Tablet formulations comprising amoxycillin and salts of clavulanic acid
AU3777597A (en) Tablet dosage form of clavulanic acid and amoxycillin comprising a trehalose excipient
IL131201A (en) Pharmaceutical formulations comprising amoxycillin and clavulanate
HK1043042A1 (zh) 含有阿莫西林和棒酸鹽的藥用加工製劑
IL105966A0 (en) Preparation of clavulanic acid
HU9300034D0 (en) Derivatives of quinolone and of naphtyridone-carboxylic acid
EP0532466A3 (en) Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
PL331861A1 (en) Derivatives of propionic acid and their application
EP0821054A3 (de) Verwendung von Polyasparaginsäure und ihrer Salze
HU9202085D0 (en) Derivatives of 7-isoindolinyl-quinolone and of naphthyridone-carboxylic acid
HUP9801064A3 (en) Composition comprising amoxycillin and clavulanic acid
HU9502520D0 (en) Pharmaceutical use of substituted 4-phenyl-6-amino-nicotinic acid derivatives
AU2111095A (en) Salts of omega-3-polyunsaturated fatty acids and pharmaceutical formulations containing them
IL115125A0 (en) Pharmaceutical formulations comprising derivatives of clavulanic acid
AU1847695A (en) Pharmaceutical formulations of cntf
AU8015398A (en) Pharmaceutical formulations containing colostrum and the use of colostrum for the treatment of affections of the oral cavity
PL321456A1 (en) Method of obtaining clavulanic acid and/or its salts
AU7001796A (en) Benzoic acid compounds and medicinal use thereof
AU3363193A (en) Pharmaceutical formulations comprising a clavulanic acid salt and erithromycin derivative
GB9304745D0 (en) Use of pharmaceutical formulations
ZA949052B (en) Derivatives of 1-(2-fluorocyclopropyl)-quinolonecarboxylic acid and 1-(2-fluorocyclopropyl)- naphthyridonecarboxylic acid
AU2992295A (en) Therapeutic method and compounds of use therein
AU7191891A (en) Water soluble salts of purpuromycin and pharmaceutical formulations thereof
ZA94290B (en) Salts of 4-pyrimidinone derivatives their preparation and their therapeutic application
ZA931700B (en) Use of L-carnitine for treating carnitine-depleted HIV-seropositive patients